Derek R Duckett

发表

Design of a small molecule against an oncogenic noncoding RNA

Matthew D Disney, Donald G Phinney, M. Disney, 2016, Proceedings of the National Academy of Sciences.

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

Robert A Copeland, Anthony E Choudhry, T. Gilmer, 2008, Cancer research.

Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.

M. Cameron, T. Kamenecka, Y. Shin, 2013, Bioorganic & medicinal chemistry letters.

Identification of an EGFRvIII-JNK2-HGF/c-Met–Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion

M. Fallahi, Y. Ling, V. Quereda, 2015, Molecular Pharmacology.

Identification of an EGFRvIII-JNK 2-HGF / c-Met – Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion s

M. Fallahi, Y. Ling, V. Quereda, 2015 .

Metabolism considerations for kinase inhibitors in cancer treatment

M. Cameron, Derek R Duckett, D. Duckett, 2010, Expert opinion on drug metabolism & toxicology.

Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas

Yuan Ren, J. Tao, Xiaohong Zhao, 2021, Haematologica.

Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase

Mingxiang Teng, W. Roush, M. Aceti, 2020, Molecular Cancer Therapeutics.

Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.

M. Cameron, W. Roush, Claudia H. Ruiz, 2017, Bioorganic & medicinal chemistry.

Therapeutic targeting of casein kinase 1δ in breast cancer

Jenny C. Chang, M. Fallahi, J. Cleveland, 2015, Science Translational Medicine.

Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties.

J. Cleveland, S. Schürer, M. Cameron, 2013, Bioorganic & medicinal chemistry letters.

Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.

T. Spicer, P. Hodder, E. Sturchler, 2014, Assay and drug development technologies.

The promise and current status of CDK12/13 inhibition for the treatment of cancer.

S. Tadesse, Derek R Duckett, D. Duckett, 2020, Future medicinal chemistry.

A predictive nuclear translocation assay for spliced x-box-binding protein 1 identifies compounds with known organ toxicities.

T. Schroeter, C. Hahmann, Derek R Duckett, 2011, Assay and drug development technologies.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

Kyle A. Emmitte, Masaaki Furuta, N. Noro, 2007, Molecular Cancer Therapeutics.

Autophagy is inhibited by ubiquitin ligase activity in the nervous system

A. Giles, Muriel Desbois, Derek R Duckett, 2019, Nature Communications.

A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1

Kunhong Xiao, Sudarshan Rajagopal, Wayne Grant, 2011, Nature.

Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.

M. Zhang, Haitao Ji, V. Quereda, 2021, Journal of medicinal chemistry.

Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target.

U. Rix, E. Schönbrunn, E. Haura, 2023, ACS chemical biology.

Stress-induced nuclear import of apoptosis signal-regulating kinase 1 is mediated by karyopherin α2/β1 heterodimer.

E. Sturchler, P. McDonald, D. Feurstein, 2013, Biochimica et biophysica acta.

Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.

P. Griffin, D. Kojetin, Naresh Kumar, 2011, ACS chemical biology.

Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.

Li Lin, P. Lograsso, M. Cameron, 2011, ACS chemical neuroscience.

Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.

P. Lograsso, J. Habel, M. Cameron, 2010, Journal of medicinal chemistry.

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells

Louis Scampavia, Franck Madoux, Timothy P Spicer, 2018, SLAS discovery : advancing life sciences R & D.

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

K. Tsai, U. Rix, B. Czerniecki, 2021, Cancer Immunology Research.

Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ.

S. Knapp, A. Chaikuad, W. Roush, 2023, Journal of medicinal chemistry.

Synthesis of potent bicyclic bisarylimidazole c-Jun N-terminal kinase inhibitors by catalytic C-H bond activation.

P. Lograsso, J. Ellman, R. Bergman, 2007, Journal of the American Chemical Society.

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

G. Warren, R. Copeland, T. J. Lansing, 2008, Journal of medicinal chemistry.

Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38*

P. Lograsso, J. Habel, Y. Ling, 2009, Journal of Biological Chemistry.

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.

W. Roush, V. Quereda, Derek R Duckett, 2019, Cancer cell.

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine

B. Czerniecki, K. Smalley, A. Basu, 2021, Cancer Immunology Research.

ASK1 and Its Role in Neurodegenerative Diseases

E. Sturchler, P. McDonald, D. Feurstein, 2011 .

9 ASK 1 and Its Role in Neurodegenerative Diseases

E. Sturchler, P. McDonald, D. Feurstein, 2014 .

Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.

M. Cameron, W. Roush, V. Quereda, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.

P. Lograsso, M. Cameron, Y. Ling, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.

P. Lograsso, J. Habel, Y. Ling, 2009, Bioorganic & medicinal chemistry letters.

3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.

P. Lograsso, J. Habel, Y. Ling, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.

P. Lograsso, M. Cameron, Y. Ling, 2014, Bioorganic & medicinal chemistry letters.

Coordination games in cancer

Joel s. Brown, R. Gatenby, K. Staňková, 2021, bioRxiv.

Chroman-3-amides as potent Rho kinase inhibitors.

P. Lograsso, S. Schürer, M. Cameron, 2008, Bioorganic & medicinal chemistry letters.

βarrestin-1 regulates DNA repair by acting as an E3-ubiquitin ligase adaptor for 53BP1

K. Xiao, Makoto R. Hara, P. McDonald, 2019, Cell Death & Differentiation.

Antiproliferation Activity of a Small Molecule Repressor of Liver Receptor Homolog 1

Graham M. West, P. Griffin, W. Roush, 2015, Molecular Pharmacology.

Synthesis and SAR of 2,4-diaminopyrimidines as potent c-jun N-terminal kinase inhibitors

M. Cameron, Y. Ling, T. Kamenecka, 2012 .

Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.

M. Cameron, T. Kamenecka, Claudia H. Ruiz, 2011, Bioorganic & medicinal chemistry letters.

In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors.

W. Roush, J. Choi, Derek R Duckett, 2017, ACS medicinal chemistry letters.

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.

J. Cleveland, J. Pinilla-Ibarz, W. Roush, 2020, Blood advances.

Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors

J. Cleveland, L. H. Rosenberg, Derek R Duckett, 2015, Journal of biomolecular screening.

A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma

B. Czerniecki, N. Tran, M. Vogelbaum, 2022, Neuro-oncology.

Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers

B. Fridley, Mingxiang Teng, Derek R Duckett, 2021, bioRxiv.

Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.

P. Lograsso, M. Cameron, Y. Ling, 2011, Bioorganic & medicinal chemistry letters.

In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors.

W. Roush, Derek R Duckett, Wayne Grant, 2017, ACS medicinal chemistry letters.

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

B. Czerniecki, N. Tran, K. Smalley, 2021, Journal of visualized experiments : JoVE.

Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties.

J. Cleveland, S. Schürer, M. Cameron, 2013, Bioorganic & medicinal chemistry letters.

Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.

P. Lograsso, S. Schürer, J. Pocas, 2009, Bioorganic & medicinal chemistry letters.